Gain Therapeutics announces grant award by Eurostars with Innosuisse

Gain Therapeutics announced that Eurostars and Innosuisse have awarded a grant in the aggregate amount of EUR 1.2M to a consortium led by Gain Therapeutics which includes the Institute for Research in Biomedicine, Newcells Biotech and the University of Helsinki. This grant supports a research project to develop novel small molecule allosteric regulators against Alpha-1 Antitrypsin, AAT, Deficiency, a rare genetic condition that can result in serious lung and liver diseases. "We are pleased that Eurostars and Innosuisse recognize that Gain Therapeutics’ allosteric small molecule regulators provide a new approach to address AAT deficiency-related metabolic diseases. We look forward to advancing our AAT program with this consortium, which combines our unique targeting approach with novel in vitro and in vivo models. This grant validates the capability of our computational discovery platform SEE-Tx to identify previously unknown allosteric binding sites on protein targets in CNS, oncology and now metabolic disease," said Dr. Manolo Bellotto, Chief Strategic Officer and General Manager at Gain Therapeutics.